Compare RYAN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAN | BMRN |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 13.0B |
| IPO Year | 2021 | 1999 |
| Metric | RYAN | BMRN |
|---|---|---|
| Price | $41.91 | $66.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | $50.88 | ★ $88.22 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $3,051,126,000.00 | $1,313,646,000.00 |
| Revenue This Year | $15.78 | $15.02 |
| Revenue Next Year | $12.49 | $12.23 |
| P/E Ratio | $86.72 | ★ $86.55 |
| Revenue Growth | ★ 21.28 | 17.62 |
| 52 Week Low | $29.28 | $49.26 |
| 52 Week High | $59.19 | $70.98 |
| Indicator | RYAN | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 56.83 |
| Support Level | $40.43 | $58.03 |
| Resistance Level | $43.10 | $70.98 |
| Average True Range (ATR) | 1.33 | 1.56 |
| MACD | -0.23 | -0.34 |
| Stochastic Oscillator | 25.36 | 46.31 |
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.